ArticleJournal of natural medicines2025
Nobiletin alleviates hypoxia-induced pulmonary hypertension by inhibiting calcium-sensing receptor.
Article in Journal of natural medicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pulmonary hypertension is a disease characterized by complex diagnosis, challenging treatment, and a shortage of clinical medications. Among them, Group III pulmonary hypertension, which is caused by lung diseases and/or hypoxia, has the second-largest number of patients. Currently, there are extremely few clinically guided medications for Group III pulmonary hypertension, and their efficacy is limited. It is urgent to find new and effective drugs. To explore the potential efficacy of nobiletin in treating hypoxia-induced pulmonary hypertension and its underlying mechanism, the hypoxia-induced pulmonary hypertension rat model was copied by 6-week consecutive hypoxia. Nobiletin or sildenafil was administered daily via gavage for 2 weeks. Subsequently, hemodynamic parameters, HE staining and Masson staining, cytoplasmic calcium level of pulmonary arterial smooth muscle cells (PASMCs) were measured. In addition, cellular thermal shift assays, cell migration and proliferation assays, and immunoblotting were performed to explore the therapeutic effects and underlying mechanisms. Nobiletin effectively attenuated hypoxia-induced pulmonary hypertension in rat, leading to a decrease in mean pulmonary artery pressure, pulmonary vascular resistance, amelioration of vascular remodeling. Furthermore, nobiletin effectively inhibited the elevation of intracellular calcium level, the migration and proliferation of PASMCs induced by hypoxia. The mechanism underlying was attributed to the fact that nobiletin reduced calcium-sensing receptor (CaSR) activity by inhibiting the formation of CaSR dimers. Nobiletin effectively alleviated hypoxia-induced pulmonary hypertension by inhibiting CaSR activity. Nobiletin may be a potential candidate for the treatment of Group III pulmonary hypertension.
Indexed as
Identifiers
40581895What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.